前立腺癌の尿中Hydroxyprolineの検討

Abstract

Urinary hydroxyproline has been attracted attention as an early index of bony metastasis in carcinoma of the prostate. We estimated urinary hydroxyproline excretion in patients with carcinoma of the prostate and the following results were obtained. (1) Hydroxyproline measurements in 24-hour urine samples of 23 normal male adults were done In order to determine the normal value. The results indicated that 24-hour urinary hydroxyproline output was 30.7±7.1 mg/day (mean±SD) and 24-hour urinary hydroxyproline/creatinine ratio was 24.6±3.7 mg/g (mean±SD). (2) Both 24-hour urinary hydroxyproline excretion and hydroxyproline/creatinine ratio were elevated in patients with carcinoma of the prostate with osseous metastasis when compared to those of normal male adults, patients with benign prostatic hypertrophy and patients with carcinoma of the prostate without osseous metastasis (P<0.01). (3) Both 24-hour urinary hydroxyproline excretion and hydroxyproline/creatinine ratio tended to decrease in patients with carcinoma of the prostate with osseous metastasis who were responding favorably to hormonal manipulation. 4) Hydroxyproline and hydroxyproline/creatinine ratio in early morning urine and a spot urine were well correlated with those in 24-hour urine, thus, an early morning urine or a spot urine could be the specimen. This results presented here indicate that urinary hydroxyproline excretion may be a sensitive tumor marker of bony metastasis in carcinoma of the prostate.